Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

ergocalciferol

×

Overview

What is VITAMIN D?

Ergocalciferol Capsules, USP are a synthetic calcium regulator for oral administration.

Ergocalciferol is a white, colorless crystal, insoluble in water, soluble in organic solvents, and slightly soluble in vegetable oils. It is affected by air and by light. Ergosterol or provitamin D is found in plants and yeast and has no antirachitic activity.

There are more than 10 substances belonging to a group of steroid compounds, classified as having vitamin D or antirachitic activity.

One USP unit of vitamin D is equivalent to one International Unit (IU), and 1 mcg of vitamin D is equal to 40 USP Units.

Each capsule contains Vitamin D (Ergocalciferol) 1.25 mg equivalent to 50,000 USP Units in an edible vegetable oil.

Ergocalciferol, also called vitamin D, is 9,10-secoergosta-5,7,10(19), 22-tetraen-3-ol, (3β,5Z,7E,22)-; (CHO) with a molecular weight of 396.65, and has the following structural formula:

Inactive Ingredients



What does VITAMIN D look like?



What are the available doses of VITAMIN D?

Sorry No records found.

What should I talk to my health care provider before I take VITAMIN D?

Sorry No records found

How should I use VITAMIN D?

Ergocalciferol Capsules, USP are indicated for use in the treatment of hypoparathyroidism, refractory rickets, also known as vitamin D resistant rickets, and familial hypophosphatemia.

THE RANGE BETWEEN THERAPEUTIC AND TOXIC DOSES IS NARROW.

Vitamin D Resistant Rickets:

Hypoparathyroidism:

DOSAGE MUST BE INDIVIDUALIZED UNDER CLOSE MEDICAL SUPERVISION.

Calcium intake should be adequate. Blood calcium and phosphorus determinations must be made every 2 weeks or more frequently if necessary.

X-rays of the bones should be taken every month until condition is corrected and stabilized.


What interacts with VITAMIN D?

Ergocalciferol Capsules, USP are contraindicated in patients with hypercalcemia, malabsorption syndrome, abnormal sensitivity to the toxic effects of vitamin D, and hypervitaminosis D.



What are the warnings of VITAMIN D?

When penicillin therapy is indicated, it should be initiated only after a comprehensive patient drug and allergy history has been obtained. If an allergic reaction occurs, the drug should be discontinued and the patient should receive supportive treatment, e.g., artificial maintenance of ventilation, pressor amines, antihistamines and corticosteroids. Individuals with a history of penicillin hypersensitivity may also experience allergic reactions when treated with a cephalosporin.

Hypersensitivity to vitamin D may be one etiologic factor in infants with idiopathic hypercalcemia. In these cases vitamin D must be strictly restricted.

Keep out of the reach of children.


What are the precautions of VITAMIN D?

General

Vitamin D administration from fortified foods, dietary supplements, self-administered and prescription drug sources should be evaluated. Therapeutic dosage should be readjusted as soon as there is clinical improvement. Dosage levels must be individualized and great care exercised to prevent serious toxic effects. IN VITAMIN D RESISTANT RICKETS THE RANGE BETWEEN THERAPEUTIC AND TOXIC DOSES IS NARROW. When high therapeutic doses are used progress should be followed with frequent blood calcium determinations.

In the treatment of hypoparathyroidism, intravenous calcium, parathyroid hormone, and/or dihydrotachysterol may be required.

Maintenance of a normal serum phosphorus level by dietary phosphate restriction and/or administration of aluminum gels as intestinal phosphate binders in those patients with hyperphosphatemia as frequently seen in renal osteodystrophy is essential to prevent metastatic calcification.

Adequate dietary calcium is necessary for clinical response to vitamin D therapy.

This product contains FD&C Yellow No. 5 (tartrazine) which may cause allergic-type reactions (including bronchial asthma) in certain susceptible individuals. Although the overall incidence of FD&C Yellow No. 5 (tartrazine) sensitivity in the general population is low, it is frequently seen in patients who also have aspirin hypersensitivity.

Protect from light.

Drug Interactions

Mineral oil interferes with the absorption of fat-soluble vitamins, including vitamin D preparations.

Administration of thiazide diuretics to hypoparathyroid patients who are concurrently being treated with Ergocalciferol Capsules, USP may cause hypercalcemia.

Carcinogenesis, Mutagenesis, Impairment of Fertility

No long-term animal studies have been performed to evaluate the drug's potential in these areas.

Pregnancy Category C

Animal reproduction studies have shown fetal abnormalities in several species associated with hypervitaminosis D. These are similar to the supravalvular aortic stenosis syndrome described in infants by Black in England (1963). This syndrome was characterized by supravalvular aortic stenosis, elfin facies, and mental retardation. For the protection of the fetus, therefore, the use of vitamin D in excess of the recommended dietary allowance during normal pregnancy should be avoided unless, in the judgment of the physician, potential benefits in a specific, unique case outweigh the significant hazards involved. The safety in excess of 400 USP Units of vitamin D daily during pregnancy has not been established.

Nursing Mothers

Caution should be exercised when Ergocalciferol Capsules, USP are administered to a nursing woman. In a mother given large doses of vitamin D, 25-hydroxycholecalciferol appeared in the milk and caused hypercalcemia in her child. Monitoring of the infant's serum calcium concentration is required in that case (Goldberg, 1972).

Pediatric Use

Pediatric doses must be individualized (see ).

Geriatric Use

Clinical studies of Ergocalciferol Capsules, USP did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. A few published reports have suggested that the absorption of orally administered vitamin D may be attenuated in elderly compared to younger, individuals. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.


What are the side effects of VITAMIN D?

Hypervitaminosis D is characterized by effects on the following organ system:

Renal:

CNS:

Soft Tissues:

Skeletal:

Decline in the average rate of linear growth and increased mineralization of bones in infants and children (dwarfism) vague aches, stiffness, and weakness.

Gastrointestinal:

Metabolic:

Call your doctor for medical advice about side effects. You may report side effects to Strides Pharma Inc. at 1-877-244-9825 or go to www.stridesshasun.com


What should I look out for while using VITAMIN D?

Ergocalciferol Capsules, USP are contraindicated in patients with hypercalcemia, malabsorption syndrome, abnormal sensitivity to the toxic effects of vitamin D, and hypervitaminosis D.

Hypersensitivity to vitamin D may be one etiologic factor in infants with idiopathic hypercalcemia. In these cases vitamin D must be strictly restricted.

Keep out of the reach of children.


What might happen if I take too much VITAMIN D?


How should I store and handle VITAMIN D?

Product: 71335-0278NDC: 71335-0278-1 12 CAPSULE in a BOTTLENDC: 71335-0278-9 60 CAPSULE in a BOTTLENDC: 71335-0278-7 15 CAPSULE in a BOTTLENDC: 71335-0278-4 4 CAPSULE in a BOTTLENDC: 71335-0278-5 20 CAPSULE in a BOTTLENDC: 71335-0278-2 30 CAPSULE in a BOTTLENDC: 71335-0278-8 120 CAPSULE in a BOTTLENDC: 71335-0278-3 100 CAPSULE in a BOTTLENDC: 71335-0278-6 8 CAPSULE in a BOTTLEProduct: 71335-0278NDC: 71335-0278-1 12 CAPSULE in a BOTTLENDC: 71335-0278-9 60 CAPSULE in a BOTTLENDC: 71335-0278-7 15 CAPSULE in a BOTTLENDC: 71335-0278-4 4 CAPSULE in a BOTTLENDC: 71335-0278-5 20 CAPSULE in a BOTTLENDC: 71335-0278-2 30 CAPSULE in a BOTTLENDC: 71335-0278-8 120 CAPSULE in a BOTTLENDC: 71335-0278-3 100 CAPSULE in a BOTTLENDC: 71335-0278-6 8 CAPSULE in a BOTTLEProduct: 71335-0278NDC: 71335-0278-1 12 CAPSULE in a BOTTLENDC: 71335-0278-9 60 CAPSULE in a BOTTLENDC: 71335-0278-7 15 CAPSULE in a BOTTLENDC: 71335-0278-4 4 CAPSULE in a BOTTLENDC: 71335-0278-5 20 CAPSULE in a BOTTLENDC: 71335-0278-2 30 CAPSULE in a BOTTLENDC: 71335-0278-8 120 CAPSULE in a BOTTLENDC: 71335-0278-3 100 CAPSULE in a BOTTLENDC: 71335-0278-6 8 CAPSULE in a BOTTLEProduct: 71335-0278NDC: 71335-0278-1 12 CAPSULE in a BOTTLENDC: 71335-0278-9 60 CAPSULE in a BOTTLENDC: 71335-0278-7 15 CAPSULE in a BOTTLENDC: 71335-0278-4 4 CAPSULE in a BOTTLENDC: 71335-0278-5 20 CAPSULE in a BOTTLENDC: 71335-0278-2 30 CAPSULE in a BOTTLENDC: 71335-0278-8 120 CAPSULE in a BOTTLENDC: 71335-0278-3 100 CAPSULE in a BOTTLENDC: 71335-0278-6 8 CAPSULE in a BOTTLEProduct: 71335-0278NDC: 71335-0278-1 12 CAPSULE in a BOTTLENDC: 71335-0278-9 60 CAPSULE in a BOTTLENDC: 71335-0278-7 15 CAPSULE in a BOTTLENDC: 71335-0278-4 4 CAPSULE in a BOTTLENDC: 71335-0278-5 20 CAPSULE in a BOTTLENDC: 71335-0278-2 30 CAPSULE in a BOTTLENDC: 71335-0278-8 120 CAPSULE in a BOTTLENDC: 71335-0278-3 100 CAPSULE in a BOTTLENDC: 71335-0278-6 8 CAPSULE in a BOTTLEProduct: 71335-0278NDC: 71335-0278-1 12 CAPSULE in a BOTTLENDC: 71335-0278-9 60 CAPSULE in a BOTTLENDC: 71335-0278-7 15 CAPSULE in a BOTTLENDC: 71335-0278-4 4 CAPSULE in a BOTTLENDC: 71335-0278-5 20 CAPSULE in a BOTTLENDC: 71335-0278-2 30 CAPSULE in a BOTTLENDC: 71335-0278-8 120 CAPSULE in a BOTTLENDC: 71335-0278-3 100 CAPSULE in a BOTTLENDC: 71335-0278-6 8 CAPSULE in a BOTTLEProduct: 71335-0278NDC: 71335-0278-1 12 CAPSULE in a BOTTLENDC: 71335-0278-9 60 CAPSULE in a BOTTLENDC: 71335-0278-7 15 CAPSULE in a BOTTLENDC: 71335-0278-4 4 CAPSULE in a BOTTLENDC: 71335-0278-5 20 CAPSULE in a BOTTLENDC: 71335-0278-2 30 CAPSULE in a BOTTLENDC: 71335-0278-8 120 CAPSULE in a BOTTLENDC: 71335-0278-3 100 CAPSULE in a BOTTLENDC: 71335-0278-6 8 CAPSULE in a BOTTLEProduct: 71335-0278NDC: 71335-0278-1 12 CAPSULE in a BOTTLENDC: 71335-0278-9 60 CAPSULE in a BOTTLENDC: 71335-0278-7 15 CAPSULE in a BOTTLENDC: 71335-0278-4 4 CAPSULE in a BOTTLENDC: 71335-0278-5 20 CAPSULE in a BOTTLENDC: 71335-0278-2 30 CAPSULE in a BOTTLENDC: 71335-0278-8 120 CAPSULE in a BOTTLENDC: 71335-0278-3 100 CAPSULE in a BOTTLENDC: 71335-0278-6 8 CAPSULE in a BOTTLEProduct: 71335-0278NDC: 71335-0278-1 12 CAPSULE in a BOTTLENDC: 71335-0278-9 60 CAPSULE in a BOTTLENDC: 71335-0278-7 15 CAPSULE in a BOTTLENDC: 71335-0278-4 4 CAPSULE in a BOTTLENDC: 71335-0278-5 20 CAPSULE in a BOTTLENDC: 71335-0278-2 30 CAPSULE in a BOTTLENDC: 71335-0278-8 120 CAPSULE in a BOTTLENDC: 71335-0278-3 100 CAPSULE in a BOTTLENDC: 71335-0278-6 8 CAPSULE in a BOTTLEProduct: 71335-0278NDC: 71335-0278-1 12 CAPSULE in a BOTTLENDC: 71335-0278-9 60 CAPSULE in a BOTTLENDC: 71335-0278-7 15 CAPSULE in a BOTTLENDC: 71335-0278-4 4 CAPSULE in a BOTTLENDC: 71335-0278-5 20 CAPSULE in a BOTTLENDC: 71335-0278-2 30 CAPSULE in a BOTTLENDC: 71335-0278-8 120 CAPSULE in a BOTTLENDC: 71335-0278-3 100 CAPSULE in a BOTTLENDC: 71335-0278-6 8 CAPSULE in a BOTTLE


×

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

The in vivo synthesis of the major biologically active metabolites of vitamin D occurs in two steps. The first hydroxylation of ergocalciferol takes place in the liver (to 25-hydroxyvitamin D) and the second in the kidneys (to 1, 25-dihydroxyvitamin D). Vitamin D metabolites promote the active absorption of calcium and phosphorus by the small intestine, thus elevating serum calcium and phosphate levels sufficiently to permit bone mineralization. Vitamin D metabolites also mobilize calcium and phosphate from bone and probably increase the reabsorption of calcium and perhaps also of phosphate by the renal tubules.

There is a time lag of 10 to 24 hours between the administration of vitamin D and the initiation of its action in the body due to the necessity of synthesis of the active metabolites in the liver and kidneys. Parathyroid hormone is responsible for the regulation of this metabolism in the kidneys.

Non-Clinical Toxicology
Ergocalciferol Capsules, USP are contraindicated in patients with hypercalcemia, malabsorption syndrome, abnormal sensitivity to the toxic effects of vitamin D, and hypervitaminosis D.

Hypersensitivity to vitamin D may be one etiologic factor in infants with idiopathic hypercalcemia. In these cases vitamin D must be strictly restricted.

Keep out of the reach of children.

Mineral oil interferes with the absorption of fat-soluble vitamins, including vitamin D preparations.

Administration of thiazide diuretics to hypoparathyroid patients who are concurrently being treated with Ergocalciferol Capsules, USP may cause hypercalcemia.

Vitamin D administration from fortified foods, dietary supplements, self-administered and prescription drug sources should be evaluated. Therapeutic dosage should be readjusted as soon as there is clinical improvement. Dosage levels must be individualized and great care exercised to prevent serious toxic effects. IN VITAMIN D RESISTANT RICKETS THE RANGE BETWEEN THERAPEUTIC AND TOXIC DOSES IS NARROW. When high therapeutic doses are used progress should be followed with frequent blood calcium determinations.

In the treatment of hypoparathyroidism, intravenous calcium, parathyroid hormone, and/or dihydrotachysterol may be required.

Maintenance of a normal serum phosphorus level by dietary phosphate restriction and/or administration of aluminum gels as intestinal phosphate binders in those patients with hyperphosphatemia as frequently seen in renal osteodystrophy is essential to prevent metastatic calcification.

Adequate dietary calcium is necessary for clinical response to vitamin D therapy.

This product contains FD&C Yellow No. 5 (tartrazine) which may cause allergic-type reactions (including bronchial asthma) in certain susceptible individuals. Although the overall incidence of FD&C Yellow No. 5 (tartrazine) sensitivity in the general population is low, it is frequently seen in patients who also have aspirin hypersensitivity.

Protect from light.

Hypervitaminosis D is characterized by effects on the following organ system:

Renal:

CNS:

Soft Tissues:

Skeletal:

Decline in the average rate of linear growth and increased mineralization of bones in infants and children (dwarfism) vague aches, stiffness, and weakness.

Gastrointestinal:

Metabolic:

Call your doctor for medical advice about side effects. You may report side effects to Strides Pharma Inc. at 1-877-244-9825 or go to www.stridesshasun.com

×

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

×

Review

Rate this treatment and share your opinion


Learn about User Reviews

Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

Effectiveness (required)

This medication has worked for me.




Ease of Use (required)

This medication has been easy for me to use.




Satisfaction (required)

Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
×

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
×

Tips

Tips

×

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).